Ulrichs T, Kaufmann S H E
Max-Planck-Institut für Infektionsbiologie, Berlin.
Internist (Berl). 2003 Nov;44(11):1374-84. doi: 10.1007/s00108-003-1057-7.
Tuberculosis is an ancient health problem that is still not under control worldwide. High infection rates with the etiologic pathogen, Mycobacterium tuberculosis, persisting within the host organism and waiting for the opportunity to disseminate when the immune system is suppressed, and the long and cost-intensive chemotherapeutic treatment urgently require the development of a novel vaccine. This article reviews the immune response to M. tuberculosis infection resulting in new strategies for the improvement of the available vaccine Mycobacterium bovis BCG or for the development of alternative vaccines. A new vaccine should elicit a better immune response than the natural infection and reliably protect from TB disease, regardless if given prior or post infection with M. tuberculosis.
结核病是一个古老的健康问题,在全球范围内仍未得到控制。致病性病原菌结核分枝杆菌的高感染率持续存在于宿主体内,等待免疫系统受到抑制时传播的机会,而漫长且成本高昂的化疗迫切需要开发新型疫苗。本文综述了针对结核分枝杆菌感染的免疫反应,从而产生了改进现有疫苗卡介苗或开发替代疫苗的新策略。一种新型疫苗应能引发比自然感染更好的免疫反应,并能可靠地预防结核病,无论在结核分枝杆菌感染之前还是之后接种。